Impact of Hemodilution on Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia

被引：0

作者：

Tettero, Jesse ^{[1
,2
]}

Heidinga, Maaike ^{[1
]}

Mocking, Tim ^{[1
]}

Kelder, Angele ^{[1
]}

Scholten, Willemijn ^{[1
]}

Snel, Alexander ^{[1
]}

Ngai, Lok Lam ^{[1
]}

Bachas, Costa ^{[1
]}

van de Loosdrecht, Arjan ^{[1
]}

Ossenkoppele, Gert ^{[1
]}

de Leeuw, David ^{[1
]}

Janssen, Jeroen ^{[3
]}

Cloos, Jacqueline ^{[1
]}

机构：

[1] Amsterdam UMC, Amsterdam, Netherlands

[2] Virginia Tech, FBRI Canc Res Ctr, Washington, DC USA

[3] Radboudumc, Nijmegen, Netherlands

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

AML; acute myeloid leukemia; hemodilution; measurable residual disease; MRD;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

AML-348

引用

页码：S307 / S308

页数：2

共 50 条

[21] Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia
Hasserjian, Robert P.
Steensma, David P.
Graubert, Timothy A.
Ebert, Benjamin L.
BLOOD, 2020, 135 (20) : 1729 - 1738
[22] Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow
Godwin, Colin D.
Zhou, Yi
Othus, Megan
Asmuth, Mallette M.
Shaw, Carole M.
Gardner, Kelda M.
Wood, Brent L.
Walter, Roland B.
Estey, Elihu H.
BLOOD, 2021, 137 (04) : 569 - 572
[23] Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia
Yun-wei Zhang
Long Su
Ye-hui Tan
Hai Lin
Xiao-liang Liu
Qiu-ju Liu
Jing-nan Sun
Ming Zhang
Ya-zhe Du
Fei Song
Wei Han
Su-jun Gao
Annals of Hematology, 2023, 102 : 337 - 347
[24] Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia
Yoest, Jennifer M.
Shirai, Cara Lunn
Duncavage, Eric J.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
[25] Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia
Paiva, Bruno
Vidriales, Maria-Belen
Sempere, Amparo
Tarin, Fabian
Colado, Enrique
Benavente, Celina
Cedena, Maria-Teresa
Sanchez, Joaquin
Caballero-Velazquez, Teresa
Cordon, Lourdes
Garces, Juan-Jose
Simoes, Catia
Martinez-Cuadron, David
Bernal, Teresa
Botella, Carmen
Grille, Sofia
Serrano, Josefina
Rodriguez-Medina, Carlos
Algarra, Lorenzo
Alonso-Dominguez, Juan-Manuel
Amigo, Maria-Luz
Barrios, Manuel
Garcia-Boyero, Raimundo
Colorado, Mercedes
Perez-Oteyza, Jaime
Perez-Encinas, Manuel
Costilla-Barriga, Lisette
Sayas, Maria-Jose
Perez, Olga
Gonzalez-Diaz, Marcos
Perez-Simon, Jose A.
Martinez-Lopez, Joaquin
Sossa, Claudia
Orfao, Alberto
San Miguel, Jesus F.
Sanz, Miguel-Angel
Montesinos, Pau
LEUKEMIA, 2021, 35 (08) : 2358 - 2370
[26] Perspective on measurable residual disease testing in acute myeloid leukemia
Walter, Roland B.
LEUKEMIA, 2024, 38 (01) : 10 - 13
[27] Detection methods and prognosis implications of measurable residual disease in acute myeloid leukemia
Zhao, Zihan
Lan, Jianping
ANNALS OF HEMATOLOGY, 2024, 103 (12) : 4869 - 4881
[28] Measurable residual disease in multiple myeloma and in acute myeloid leukemia, an evolving topic
Castelli, Germana
Pelosi, Elvira
Testa, Ugo
ANNALI DELL ISTITUTO SUPERIORE DI SANITA, 2021, 57 (04): : 300 - 313
[29] Evaluating measurable residual disease in acute myeloid leukemia
Ravandi, Farhad
Walter, Roland B.
Freeman, Sylvie D.
BLOOD ADVANCES, 2018, 2 (11) : 1356 - 1366
[30] Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible?
Brooimans, Rik A.
van der Velden, Vincent H. J.
Boeckx, Nancy
Slomp, Jennita
Preijers, Frank
te Marvelde, Jeroen G.
Van, Ngoc M.
Heijs, Antoinette
Huys, Erik
van der Holt, Bronno
de Greef, Georgine E.
Kelder, Angele
Schuurhuis, Gerrit Jan
LEUKEMIA RESEARCH, 2019, 76 : 39 - 47

← 1 2 3 4 5 →